Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors

Multiple myeloma (MM) is a hematologic malignancy characterized by severely profound immune dysfunction. Therefore, the efficacy of drugs targeting the immune environments, such as immune checkpoint inhibitors (ICIs), is of high clinical importance. However, several clinical trials evaluating ICIs i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulikowska de Nałęcz, Anna, Ciszak, Lidia, Usnarska-Zubkiewicz, Lidia, Pawlak, Edyta, Frydecka, Irena, Szmyrka, Magdalena, Kosmaczewska, Agata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056286/
https://www.ncbi.nlm.nih.gov/pubmed/36982802
http://dx.doi.org/10.3390/ijms24065730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056286/
https://www.ncbi.nlm.nih.gov/pubmed/36982802
http://dx.doi.org/10.3390/ijms24065730

Ejemplares similares